Gyros Launches Nanoliter-scale Immunoassay System Gyrolab xPlore™ at SLAS2015 Conference


Gyros AB, a pioneer in miniaturizing and automating immunoassays at nanoliter-scale, is launching a new instrument, Gyrolab xPlore™, at the 2015 Society for Laboratory Automation and Screening Conference (SLAS2015) in Washington, D.C., Feb. 7 to 11.

A smaller version of the widely used five-CD Gyrolab™ xP workstation, Gyrolab xPlore is a more compact, cost-effective, single-CD tool that makes automated nanoliter-scale immunoassays accessible to laboratories of every size. Using proven microfluidic technology, Gyrolab xPlore optimizes immunoassay development, enabling faster assay development, validation and high-throughput analyses in less time than with manual ELISA or semi-automated methods.

Gyros’ technology delivers high-quality data with broad dynamic ranges and excellent reproducibility while dramatically reducing sample and reagent consumption. Gyrolab systems use precise, automated control of centrifugal and capillary forces to steer liquid flow through nanoliter-scale microfluidic structures contained within Gyrolab CDs, automating the assay workflow.

“Gyrolab xPlore is a cost-effective tool that will accelerate assay development for discovery and preclinical R&D, help users meet critical data and time requirements for regulated bioanalysis and improve efficiency in bioprocess development and quality control,” said Dan Calvo, president and CEO of Gyros. “Gyrolab xPlore uses the same CD-based technology found in our widely adopted Gyrolab xP, but its cost and size make it more accessible to a larger range of laboratories doing immunoassays.”

Gyros is showcasing Gyrolab xPlore in Booth 649 at SLAS2015 and is presenting “Automated Nanoliter-scale Immunoassays: Expanding Discovery Productivity for Bioanalysis” in room 149b at 2 p.m. Monday, Feb. 9. To see Gyrolab xPlore in action, visit

For Gyros AB

Lea Studer
SCORR Marketing
Phone: +1 308.237.5567

Notes to editors:

High resolution images:

About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. Gyros’ immunoassay platforms increase productivity and efficiency during development of biotherapeutics and vaccines, saving time, labor and sample. Major biopharmaceutical companies and their service providers utilize Gyros’ platforms to boost time-critical workflows and meet increasingly stringent regulatory demands.